CAR-T therapy extends life in stomach cancer
Chinese researchers have reported success in a phase II clinical trial of anti-CLDN18.2 chimeric antigen receptor T cells in refractory gastric and gastroesophageal junction cancer. The therapy significantly extended patients' lives, the report says…